In 2014 and early 2015 we carried out an FCC SAR (Specific Absorption Rate) analysis of a rechargeable neuroregulator for a client in the medical device industry. The Class III medical device is intended for treatment of obesity and obesity related disorders. The report submitted to the FCC is now in the public domain and can be accessed here:
We made extensive use of the Remcom X-FDTD simulator in this work. Some plots of 1 gr SAR average extracted from the report are shown here:
* As of 2022 EnteroMedics is now ReShape Lifesciences.
Updated November 23, 2022.